EastWest Bioscience Inc.
Other OTCTotal Valuation
EastWest Bioscience Inc. carries a market capitalization of 7,780.00, placing it among publicly traded companies globally. Its enterprise value stands at 2.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7,780.00 |
| Enterprise Value | 2.44M |
Share Statistics
EastWest Bioscience Inc. currently has 100.66M shares outstanding.
| Shares Outstanding | 100.66M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 8.36 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 147.97 |
Financial Position
EastWest Bioscience Inc. maintains a current ratio of 0.09, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.67, indicating elevated leverage, while an interest coverage ratio of -6.60 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.09 |
| Quick Ratio | 0.03 |
| Debt / Equity | 71.67 |
| Debt / EBITDA | -1.32 |
| Interest Coverage | -6.60 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 2.02 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 25.44 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.27 |
Stock Price Statistics
EastWest Bioscience Inc.'s stock has gained approximately 0% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.02 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, EastWest Bioscience Inc. generated 291,585.00 in revenue and converted that into 108,548.00 in net income, yielding earnings per share of 0.00. EBITDA reached -1.86M, while operating income came in at -1.97M.
| Revenue | 291,585.00 |
| Gross Profit | 28,908.00 |
| Operating Income | -1.97M |
| Pretax Income | -579.00 |
| Net Income | 108,548.00 |
| EBITDA | -1.86M |
| EBIT | -1.97M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
EastWest Bioscience Inc. holds 19,973.00 in cash and equivalents against 2.46M in total debt, resulting in a net debt position of 2.44M. Total book value stands at 3.17M, with working capital of -3.45M providing operational flexibility.
| Cash & Cash Equivalents | 19,973.00 |
| Total Debt | 2.46M |
| Net Debt | 2.44M |
| Equity (Book Value) | 3.17M |
| Book Value Per Share | 0.03 |
| Working Capital | -3.45M |
Cash Flow
EastWest Bioscience Inc. produced -400,491.00 in operating cash flow over the past twelve months. After subtracting -74,460.00 in capital expenditures, free cash flow totaled -474,951.00 - equivalent to 0.00 per share.
| Operating Cash Flow | -400,491.00 |
| Capital Expenditures | -74,460.00 |
| Free Cash Flow | -474,951.00 |
| FCF Per Share | 0.00 |
Margins
EastWest Bioscience Inc. operates with a gross margin of 9.91, reflecting its pricing power and cost economics. The operating margin of -674.22 and net profit margin of 37.23 provide insight into operational efficiency.
| Gross Margin | 9.91 |
| Operating Margin | -674.22 |
| Pretax Margin | -0.20 |
| Profit Margin | 37.23 |
| EBITDA Margin | -638.25 |
Scores
EastWest Bioscience Inc. posts an Altman Z-Score of -2.47, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.47 |